SG11201803642WA - Bacteria-based protein delivery - Google Patents
Bacteria-based protein deliveryInfo
- Publication number
- SG11201803642WA SG11201803642WA SG11201803642WA SG11201803642WA SG11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- basel
- rule
- november
- domains
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 241000894006 Bacteria Species 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 May 2017(26.05.2017) WIPOIPCT (10) International Publication Number WO 2017/085235 A1 (51) International Patent Classification: C12N15/70 (2006.01) C07K14/195 (2006.01) C12N15/74 (2006.01) CI2N15/62 (2006.01) C12N1/21 (2006.01) (21) International Application Number: PCT/EP2016/078087 (22) International Filing Date: (25) Filing Language: (26) Publication Language: 17 November 2016 (17.11.2016) English English (30) Priority Data: 15195493.0 19 November 2015 (19.11.2015) EP (71) Applicant: UNIVERSITAT BASEL [CH/CH]; Petersg- raben 35, 4001 Basel (CH). (72) Inventors: ITTIG, Simon; Turkheimerstr. 45, 4055 Basel (CH). AMSTUTZ, Marlise; Wittlingerstr. 140, 4058 Basel (CH). KASPER, Christoph; Ruttigerweg 4, 4600 Olten (CH). (74) Agent: SCHOELLHORN, Andreas; Austrasse 24, 4051 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) < IT) n oo n O (54) Title: BACTERIA-BASED PROTEIN DELIVERY (57) : The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of re peated domains of a heterologous protein or two or more domains of different heterologous proteins into eukaryotic cells.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15195493 | 2015-11-19 | ||
| PCT/EP2016/078087 WO2017085235A1 (en) | 2015-11-19 | 2016-11-17 | Bacteria-based protein delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803642WA true SG11201803642WA (en) | 2018-06-28 |
Family
ID=54697465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803642WA SG11201803642WA (en) | 2015-11-19 | 2016-11-17 | Bacteria-based protein delivery |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11702663B2 (en) |
| EP (1) | EP3377634B1 (en) |
| JP (1) | JP6937752B2 (en) |
| KR (1) | KR102689434B1 (en) |
| CN (1) | CN108884466B (en) |
| AU (1) | AU2016355975B2 (en) |
| CA (1) | CA3005380A1 (en) |
| CY (1) | CY1123654T1 (en) |
| DK (1) | DK3377634T3 (en) |
| EA (1) | EA039922B1 (en) |
| ES (1) | ES2830251T3 (en) |
| HK (1) | HK1256138A1 (en) |
| HR (1) | HRP20201792T1 (en) |
| HU (1) | HUE051184T2 (en) |
| IL (1) | IL259050B2 (en) |
| LT (1) | LT3377634T (en) |
| PL (1) | PL3377634T3 (en) |
| PT (1) | PT3377634T (en) |
| RS (1) | RS61046B1 (en) |
| SG (1) | SG11201803642WA (en) |
| SI (1) | SI3377634T1 (en) |
| WO (1) | WO2017085235A1 (en) |
| ZA (1) | ZA201803901B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071182A1 (en) | 2012-11-01 | 2014-05-08 | Massachusetts Institute Of Technology | Directed evolution of synthetic gene cluster |
| HUE046025T2 (en) | 2014-05-21 | 2020-01-28 | Univ Basel | Bacteria-based protein delivery |
| EP3322679A4 (en) | 2015-07-13 | 2019-07-10 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
| HUE055132T2 (en) | 2015-11-19 | 2021-11-29 | Univ Basel | Virulence attenuated bacteria for treatment of malignant solid tumors |
| WO2018115140A2 (en) | 2016-12-20 | 2018-06-28 | Universität Basel | Virulence attenuated bacteria based protein delivery |
| CN111587287A (en) | 2017-10-25 | 2020-08-25 | 皮沃特生物股份有限公司 | Methods and compositions for improved nitrogen-fixing engineered microorganisms |
| CN114480463B (en) * | 2020-10-26 | 2024-07-16 | 南京吉芮康生物科技研究院有限公司 | Novel coronavirus vaccine antigen presentation system for secreting and expressing RBD structural domain protein by attenuated salmonella and application thereof |
| MX2023004760A (en) * | 2020-10-27 | 2023-07-21 | T3 Pharmaceuticals Ag | Bacteria based protein delivery. |
| MX2023010989A (en) * | 2021-03-25 | 2023-09-27 | T3 Pharmaceuticals Ag | Pharmaceutical combinations for treating cancer. |
| CN117362451B (en) * | 2023-12-04 | 2024-03-08 | 北京质肽生物医药科技有限公司 | Fusion protein containing TEV protease, preparation method and application thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965381A (en) | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| WO2000002996A2 (en) * | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| CA2424004A1 (en) | 2000-09-26 | 2002-04-04 | Roger William Hospital | Recombinant bcg vaccines for the prevention and treatment of cancer |
| AU2002312778A1 (en) * | 2001-03-26 | 2002-10-08 | Universite Catholique De Louvain | Type iii bacterial strains for use in medicine |
| FR2862312B1 (en) * | 2003-11-13 | 2006-02-17 | Univ Grenoble 1 | TOOL FOR TRANSFER AND PRODUCTION OF PROTEINS USING THE PSEUDOMONAS TYPE III SECRETION SYSTEM |
| EP1661912A1 (en) * | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
| WO2007044406A2 (en) | 2005-10-04 | 2007-04-19 | Ludwig Institute For Cancer Research | Methods for stimulating an immune response using bacterial antigen delivery system |
| WO2008019183A2 (en) * | 2006-05-18 | 2008-02-14 | The Regents Of The University Of California | Biopolymer and protein production using type iii secretion systems of gram negative bacteria |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| WO2009115531A2 (en) | 2008-03-17 | 2009-09-24 | Universitätsklinikum Münster | Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| US8524220B1 (en) * | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| JP6936934B2 (en) * | 2013-09-24 | 2021-09-22 | メディシナ セラピューティクス インコーポレイテッド | Interleukin-4 receptor binding fusion protein and its use |
| US10143743B2 (en) * | 2013-11-18 | 2018-12-04 | Yale University | Non-replicating bacterial nanoparticle delivery system and methods of use |
| HUE046025T2 (en) | 2014-05-21 | 2020-01-28 | Univ Basel | Bacteria-based protein delivery |
| HUE055132T2 (en) | 2015-11-19 | 2021-11-29 | Univ Basel | Virulence attenuated bacteria for treatment of malignant solid tumors |
| WO2018115140A2 (en) | 2016-12-20 | 2018-06-28 | Universität Basel | Virulence attenuated bacteria based protein delivery |
-
2016
- 2016-11-17 EP EP16825704.6A patent/EP3377634B1/en active Active
- 2016-11-17 LT LTEP16825704.6T patent/LT3377634T/en unknown
- 2016-11-17 PT PT168257046T patent/PT3377634T/en unknown
- 2016-11-17 CN CN201680079453.5A patent/CN108884466B/en active Active
- 2016-11-17 HU HUE16825704A patent/HUE051184T2/en unknown
- 2016-11-17 EA EA201890914A patent/EA039922B1/en unknown
- 2016-11-17 JP JP2018526175A patent/JP6937752B2/en active Active
- 2016-11-17 ES ES16825704T patent/ES2830251T3/en active Active
- 2016-11-17 PL PL16825704T patent/PL3377634T3/en unknown
- 2016-11-17 RS RS20201344A patent/RS61046B1/en unknown
- 2016-11-17 US US15/773,526 patent/US11702663B2/en active Active
- 2016-11-17 KR KR1020187016715A patent/KR102689434B1/en active IP Right Grant
- 2016-11-17 SI SI201630974T patent/SI3377634T1/en unknown
- 2016-11-17 WO PCT/EP2016/078087 patent/WO2017085235A1/en active Application Filing
- 2016-11-17 SG SG11201803642WA patent/SG11201803642WA/en unknown
- 2016-11-17 DK DK16825704.6T patent/DK3377634T3/en active
- 2016-11-17 CA CA3005380A patent/CA3005380A1/en active Pending
- 2016-11-17 AU AU2016355975A patent/AU2016355975B2/en active Active
- 2016-11-17 IL IL259050A patent/IL259050B2/en unknown
-
2018
- 2018-06-12 ZA ZA2018/03901A patent/ZA201803901B/en unknown
- 2018-11-28 HK HK18115219.3A patent/HK1256138A1/en unknown
-
2020
- 2020-11-05 CY CY20201101044T patent/CY1123654T1/en unknown
- 2020-11-09 HR HRP20201792TT patent/HRP20201792T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6937752B2 (en) | 2021-09-22 |
| CN108884466B (en) | 2022-06-03 |
| RS61046B1 (en) | 2020-12-31 |
| WO2017085235A1 (en) | 2017-05-26 |
| JP2019500027A (en) | 2019-01-10 |
| IL259050B1 (en) | 2023-11-01 |
| CA3005380A1 (en) | 2017-05-26 |
| US11702663B2 (en) | 2023-07-18 |
| EP3377634B1 (en) | 2020-08-12 |
| HUE051184T2 (en) | 2021-03-01 |
| PT3377634T (en) | 2020-11-16 |
| BR112018009782A8 (en) | 2019-02-26 |
| HK1256138A1 (en) | 2019-09-13 |
| SI3377634T1 (en) | 2021-01-29 |
| EA039922B1 (en) | 2022-03-28 |
| HRP20201792T1 (en) | 2020-12-25 |
| EP3377634A1 (en) | 2018-09-26 |
| DK3377634T3 (en) | 2020-11-16 |
| EA201890914A1 (en) | 2018-12-28 |
| CY1123654T1 (en) | 2022-03-24 |
| IL259050A (en) | 2018-07-31 |
| PL3377634T3 (en) | 2021-03-08 |
| BR112018009782A2 (en) | 2018-11-06 |
| ZA201803901B (en) | 2019-04-24 |
| IL259050B2 (en) | 2024-03-01 |
| CN108884466A (en) | 2018-11-23 |
| ES2830251T3 (en) | 2021-06-03 |
| LT3377634T (en) | 2020-12-28 |
| US20190194670A1 (en) | 2019-06-27 |
| KR20180081798A (en) | 2018-07-17 |
| AU2016355975A1 (en) | 2018-05-10 |
| AU2016355975B2 (en) | 2022-12-08 |
| KR102689434B1 (en) | 2024-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201407343XA (en) | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201408051VA (en) | Cho expression system | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases |